![]() |
What is Multiple Myeloma?
Multiple myeloma is a hematologic malignancy that originates from plasma cells, a type of white blood cell produced in the bone marrow. Normal plasma cells are responsible for producing antibodies against infection, while cancerous plasma cells—myeloma cells—proliferate in the bone marrow, causing the patient to be unable to live a normal life and suffer from symptoms such as anemia, bone pain, fractures, decreased immunity, and hypercalcemia. symptoms, proteinuria, and renal insufficiency. The incidence of multiple myeloma is about 2 in 100,000, and it is considered the second most common malignant tumor of the blood. It commonly occurs in middle-aged and elderly people, with a high incidence in the 50-65 age group. In recent years, the age of onset has tended to be earlier. The incidence rate of men is more than that of women, with a male to female ratio of 1.6:1. With the increase of age, the incidence of multiple myeloma will also increase, which has constituted more and more serious harm to people's life and quality of life.
So can middle and late-staged multiple myeloma be treated? Minimally invasive techniques with less side effects and less trauma can help multiple myeloma patients avoid surgical resection, avoid suffering from traditional radiotherapy and chemotherapy, effectively prolong survival and improve quality of life.
For more knowledge about cancer, please click online doctors for consultation.